Opinion
Video
Author(s):
Video content above is prompted by the following:
a. Baricitinib (n=194, long term study, Senna 2024):
i. Close to 90% of patients maintained SALT ≤20 from week 52 to week 104; SALT ≤10 was achieved by over 70% of patients; clinician- and patient-reported outcomes measurements for eyebrow and eyelash showed increase in response rates between weeks 52 and 104.
ii.TEAEs were reported in 76% of patients taking baricitinib. Most TEAEs were mild to moderate. Most common TEAEs (occurred in ≥5% patients) were COVID-19 infection, upper respiratory tract infection, and headache. One event of major adverse cardiovascular event was reported (<0.1% incidence rate).